Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever
Background DNA-launched vaccine is “manufactured” in vaccinated individuals and does not require traditional vaccine manufacturing facility and technology. Goals. Using yellow fever 17D vaccine, we have provided proof-of-concept evidence that these vaccine can be launched from DNA and induce specifi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2019-03-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839576379814838272 |
|---|---|
| author | P. Pushko А. А. Ishmukhametov P. P. Bredenbeek I. S. Lukashevich |
| author_facet | P. Pushko А. А. Ishmukhametov P. P. Bredenbeek I. S. Lukashevich |
| author_sort | P. Pushko |
| collection | DOAJ |
| description | Background DNA-launched vaccine is “manufactured” in vaccinated individuals and does not require traditional vaccine manufacturing facility and technology. Goals. Using yellow fever 17D vaccine, we have provided proof-of-concept evidence that these vaccine can be launched from DNA and induce specific immune responses against pathogenic virus causing yellow fever. The infectious DNA vaccine technology is based on the transcription of the full-length genomic RNA of the live-attenuated virus from plasmid DNA in vitro and in vivo. A few ng of infectious DNA encoding the fulllength genomic RNA are required to initiate the replication of the vaccine virus in vitro. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. Electroporation in vivo has induced specific immune responses against pathogenic virus and protected mice against fatal disease. Here we describe a novel infectious DNA vaccine technology which combines advantages of naked DNA vaccination and live-attenuated vaccine efficacy. Conclusions If successful in further testing, this technology can dramatically change the way we make vaccines as well as vaccination practice. |
| format | Article |
| id | doaj-art-2a97b58e0255470fb30a27d0a99e21c4 |
| institution | Matheson Library |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| publishDate | 2019-03-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj-art-2a97b58e0255470fb30a27d0a99e21c42025-08-04T13:02:02ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942019-03-01181182510.31631/2073-3046-2019-18-1-18-25501Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow FeverP. Pushko0А. А. Ishmukhametov1P. P. Bredenbeek2I. S. Lukashevich3Medigen, Inc., Frederick, MDFederal State Budget Institution of Science «Chumakov Federal Scientific Center for Research and Development of Immune-andBiological Products of Russian Academy of Sciences», Moscow; Sechenov First Moscow State Medical University, of the Ministry of Health of the Russian Federation, MoscowDepartment of Medical Microbiology, Center of Infectious Diseases, Leiden University Medical Center, LeidenDepartment of Pharmacology and Toxicology, School of Medicine, Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, NIH Regional Bio-containment Laboratory, University of LouisvilleBackground DNA-launched vaccine is “manufactured” in vaccinated individuals and does not require traditional vaccine manufacturing facility and technology. Goals. Using yellow fever 17D vaccine, we have provided proof-of-concept evidence that these vaccine can be launched from DNA and induce specific immune responses against pathogenic virus causing yellow fever. The infectious DNA vaccine technology is based on the transcription of the full-length genomic RNA of the live-attenuated virus from plasmid DNA in vitro and in vivo. A few ng of infectious DNA encoding the fulllength genomic RNA are required to initiate the replication of the vaccine virus in vitro. The in vivo-generated viral RNA initiates limited replication of the vaccine virus, which in turn leads to efficient immunization. Electroporation in vivo has induced specific immune responses against pathogenic virus and protected mice against fatal disease. Here we describe a novel infectious DNA vaccine technology which combines advantages of naked DNA vaccination and live-attenuated vaccine efficacy. Conclusions If successful in further testing, this technology can dramatically change the way we make vaccines as well as vaccination practice.https://www.epidemvac.ru/jour/article/view/657yellow fevervirusvaccinednainfectious dnaimmunizationelectroporation |
| spellingShingle | P. Pushko А. А. Ishmukhametov P. P. Bredenbeek I. S. Lukashevich Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever Эпидемиология и вакцинопрофилактика yellow fever virus vaccine dna infectious dna immunization electroporation |
| title | Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever |
| title_full | Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever |
| title_fullStr | Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever |
| title_full_unstemmed | Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever |
| title_short | Experimental DNA-Launched Live-Attenuated Vaccines Against Yellow Fever |
| title_sort | experimental dna launched live attenuated vaccines against yellow fever |
| topic | yellow fever virus vaccine dna infectious dna immunization electroporation |
| url | https://www.epidemvac.ru/jour/article/view/657 |
| work_keys_str_mv | AT ppushko experimentaldnalaunchedliveattenuatedvaccinesagainstyellowfever AT aaishmukhametov experimentaldnalaunchedliveattenuatedvaccinesagainstyellowfever AT ppbredenbeek experimentaldnalaunchedliveattenuatedvaccinesagainstyellowfever AT islukashevich experimentaldnalaunchedliveattenuatedvaccinesagainstyellowfever |